Balyasny Asset Management’s American Well AMWL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-12,217
Closed -$96.3K 2775
2025
Q1
$96.3K Buy
+12,217
New +$116K ﹤0.01% 2683
2024
Q3
Sell
-3,501
Closed -$22.7K 2713
2024
Q2
$22.7K Buy
+3,501
New +$35.2K ﹤0.01% 2465
2024
Q1
Sell
-2,008
Closed -$59.8K 2584
2023
Q4
$59.8K Sell
2,008
-48,740
-96% -$1.2M ﹤0.01% 2403
2023
Q3
$1.19M Sell
50,748
-13,761
-21% -$465K ﹤0.01% 1524
2023
Q2
$2.71M Buy
64,509
+15,899
+33% +$702K 0.01% 1277
2023
Q1
$2.29M Buy
48,610
+12,197
+33% +$782K 0.01% 1408
2022
Q4
$2.06M Sell
36,413
-26,202
-42% -$1.89M 0.01% 1392
2022
Q3
$4.5M Buy
62,615
+30,889
+97% +$2.7M 0.01% 1059
2022
Q2
$2.74M Buy
+31,726
New +$2.37M 0.01% 1241
2022
Q1
Sell
-2,770
Closed -$335K 2449
2021
Q4
$335K Sell
2,770
-38,905
-93% -$5.93M ﹤0.01% 1717
2021
Q3
$7.59M Buy
+41,675
New +$9.04M 0.03% 677
2021
Q2
Sell
-13,720
Closed -$4.77M 1936
2021
Q1
$4.77M Buy
13,720
+12,866
+1,507% +$6.97M 0.02% 714
2020
Q4
$433K Buy
+854
New +$494K ﹤0.01% 1144

Other funds holding AMWL

Balyasny Asset Management's AMWL Position: Q2 2025 in Review

Balyasny Asset Management sold out of American Well (AMWL) in Q2 2025, closing a stake of 12,217 shares — an estimated $96.3K sold.

Balyasny Asset Management first reported a position in AMWL in Q4 2020 and held it in 13 quarters. The position peaked at $7.59M in Q3 2021. 59 funds tracked by Wall St. Rank hold AMWL as of Q2 2025.

  • Balyasny Asset Management reported no remaining American Well position as of Q2 2025 after selling out during the quarter.
  • Balyasny Asset Management sold 12,217 American Well shares in Q2 2025, an estimated $96.3K.
  • Balyasny Asset Management first reported a position in American Well in Q4 2020 and held it in 13 quarters.
  • Balyasny Asset Management's American Well position peaked at $7.59M in Q3 2021.
  • 59 funds tracked by Wall St. Rank held American Well as of Q2 2025.

Based on Balyasny Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.